New quadrivalent flu mist vaccine for children, adults

Article

The first influenza vaccine to contain 2 strains of influenza A virus and 2 strains of influenza B has been approved by the US Food and Drug Administration for use in healthy children aged 2 years and older and adults to age 49 years.

The first influenza vaccine to contain 2 strains of influenza A virus and 2 strains of influenza B has been approved by the US Food and Drug Administration for use in healthy children aged 2 years and older and adults to age 49 years.

The new quadrivalent intranasal vaccine contains weakened forms of the live influenza viruses and is administered as a spray into the nose. The addition of the second influenza B strain increases a person's overall protection against seasonal influenza infection.

Three clinical studies involving 4,000 children and adults were conducted for safety and effectiveness of the quadrivalent vaccine and demonstrated that immune responses were similar between the new formulation and the older trivalent intranasal vaccine previously approved for children and adults.

The Centers for Disease Control and Prevention recommends that all persons aged 6 months and older be vaccinated annually against seasonal influenza. Attenuated intranasal influenza vaccine should not be administered to children younger than 2 years.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
Experts discuss importance of vaccination prior to school year
Lori Handy, MD: Vaccine-only visits can help ease back-to-school gaps | Image credit: CHOP
© 2025 MJH Life Sciences

All rights reserved.